Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC. (AGN)

35
SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

03/28/2012 | 09:54am US/Eastern

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

React to this article
Latest news on ALLERGAN, INC.
06:08a ALLERGAN : Entry into a Material Definitive Agreement, Financial Statements and ..
07/01 KYTHERA BIOPHARMACEUTICALS : KYTH INVESTOR ALERT: The Law Offices of Vincent Won..
06/29 KYTHERA BIOPHARMACEUTICALS : NASDAQ:KYTH) Shareholder Notice: Investigation of T..
06/28 ALLERGAN : Selects Richmond Plastic Surgeon to Exclusively Offer Newly Released ..
06/26 ALLERGAN : Selects Richmond Plastic Surgeon to Exclusively Offer Newly Released ..
06/25 CANADA'S VALEANT APPROACHES TO BUY Z : Wsj
06/24 ALLERGAN : Recent FDA Approval of New Breast Implant Highlights the Ongoing Dema..
06/24 KYTHERA BIOPHARMACEUTICALS : Law Firm Kirby McInerney LLP Investigating Potentia..
06/24 KYTHERA BIOPHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairn..
06/24 KYTHERA BIOPHARMACEUTICALS : Investor Alert: Peiffer Rosca Wolf Law Firm Investi..
Advertisement
Income Statement Evolution
More Financials